恶性疟原虫清除依赖出芽机制:青蒿素类药物与非青蒿素药物的差异
该研究对81例口服抗疟药治疗的旅行者进行出芽(pitting)定量,发现青蒿素联合方案出芽率高(55.8%),而奎宁、甲氟喹、阿托伐醌-氯胍则低于10%。这或可部分解释非青蒿素药物寄生虫清除较慢及治疗后溶血少见的原因。
要点
- 青蒿素联合方案出芽率55.8%,非青蒿素药<10%。
- 出芽率差异可解释非青蒿素药清除疟原虫较慢。
- 非青蒿素药治疗后溶血少见或与低出芽率有关。
核心结论
- 恶性疟原虫清除在青蒿素类药物治疗时依赖出芽机制,而在阿托伐醌-氯胍或甲氟喹治疗时不依赖出芽机制。
研究设计与样本
- 对81例接受口服抗疟药治疗的旅行者进行出芽(pitting)定量研究。
主要发现
- 青蒿素联合方案出芽率为55.8%,而奎宁、甲氟喹、阿托伐醌-氯胍出芽率低于10%。
- 出芽率差异可能部分解释非青蒿素药物治疗者寄生虫清除较慢。
- 非青蒿素药物治疗后未见治疗后溶血,可能也与低出芽率有关。
临床怎么用
- 解读青蒿素与非青蒿素药物疟原虫清除动力学及溶血风险差异时可考虑出芽机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pitting, the removal of dead parasites from their host erythrocyte, has been studied in patients with severe malaria treated parenterally with quinine or artesunate, and was recently shown to contribute to delayed hemolysis, a frequent adverse event of artesunate. We quantified pitting in 81 travelers treated with oral antimalarial therapy. Pitting rate was high (55.8%) with artemisinin-based combinations, but <10% with the nonartemisinin drugs quinine, mefloquine, and atovaquone-proguanil. This may, in part, explain the slower parasite clearance in patients treated with antimalarial drugs lacking an artemisinin component, as well as the absence of posttreatment hemolysis with these drugs.
引用
- Wojnarski M, Mouri O, Chambrion C, et al. Plasmodium falciparum Clearance Is Pitting-Dependent With Artemisinin-Based Drugs but Pitting-Independent With Atovaquone-Proguanil or Mefloquine. J Infect Dis. 2019. PMID: 30877300. doi:10.1093/infdis/jiz115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。